Answers are grounded in this paper and cite their sources.
Intravenous (i.v.) minocycline is increasingly used to treat infections caused by multidrug-resistant (MDR) Acinetobacter baumannii . Despite its being approved nearly 50 years ago, published information on its pharmacokinetic (PK) profile is limited. This multicenter study examined the PK and probability of pharmacokinetic-pharmacodynamic (PK-PD) target attainment profile of i.v. minocycline in critically ill patients, with suspected or documented infection with Gram-negative bacteria.
No takes yet. Share an insight, caveat, or question.
Lodise et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: